Interaction Checker

Prescribing Resources

We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.

These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].

Detailed recommendations for interactions with experimental COVID-19 antiviral therapies.

UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies.

Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.

Click here to view PDF.

Updated 23 June 2020

Detailed recommendations for interactions with experimental COVID-19 immune therapies.

UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies.

Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.

Click here to view PDF.

Updated 17 June 2020

At-a-glance summary of interactions with experimental COVID-19 antiviral therapies.

UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies

A summary of interactions with experimental COVID-19 antiviral therapies and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 23 June 2020

At-a-glance summary of interactions with experimental COVID-19 immune therapies.

UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies

A summary of interactions with experimental COVID-19 immune therapies and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 17 June 2020

Dose recommendations for patients with renal impairment

NEW

Details of dose modifications of experimental COVID-19 therapies which may be required for patients with renal impairment are given in this PDF.

Click here to view PDF.

Updated 17 June 2020

Dose recommendations for patients with hepatic impairment

NEW

Details of dose modifications of experimental COVID-19 therapies which may be required for patients with hepatic impairment are given in this PDF.

Click here to view PDF.

Updated 17 June 2020

Administration in cases of swallowing difficulties.

UPDATED - Baricitinib and ruxolitinib added as COVID-19 immune therapies.

Advice for administering experimental COVID-19 therapies to patients who cannot swallow is given in this PDF.

Click here to view PDF.

Updated 17 June 2020

Evaluating the interaction risk of experimental COVID-19 therapies.

UPDATED - information added for baricitinib and ruxolitinib.

This document explains how we have evaluated the drug-drug interaction risk of the experimental COVID-19 therapies and gives details of their metabolism, interaction potential and cardiac effects.

Click here to view PDF.

Updated 17 June 2020

Academic Sponsors / Collaborators
Editorial Sponsors